CYduct Diagnostics, Inc. (OTC PINK: CYDX) is pleased to announce it has signed and closed an agreement to acquire all the assets of HHC PREFERRED LLC.
CYduct Diagnostics, an emerging innovator in the breast healthcare wellness segment of women’s health, said that the assets of HHC Preferred LLC (HHC) include the technology embodied in HHC”s patented, non-invasive device that is used to obtain nipple aspirate fluid (”NAF”). CYduct expects to modify the device, significantly improving yield rates previously achieved, forming the front end of CYduct’s approach to providing proteomic analysis for early identification of known biomarkers associated with breast cancer risk. NAF extracted from the mammary ducts, where nearly all breast cancer originates, provides essentially a mirror image of the microenvironment of the breast.
“This transaction signifies another step for CYduct Diagnostics in the advancement of women’s breast health wellness. This action follows a string of moves that are primed to have a profound impact on the Company’s future growth and positioning within this emerging dynamic market,” stated CYductDX CEO Dominick Gatto.
In addition to the Intellectual property, CYductDX will acquire considerable finished goods inventory, manufacturing tooling, regulatory clearance (510k or other FDA related materials) documents, notes, customer lists, data storage (server), production molds and work-in-progress, marketing collateral, other files, and tangible items. The financial terms of the Agreement were not disclosed.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Biospace